Core Viewpoint - The company reported a decline in revenue and net profit for Q1 2025, primarily due to falling coal prices, despite stable production and sales volumes [1][2]. Revenue and Profit Summary - In Q1 2025, the company achieved operating revenue of 38.39 billion yuan, a year-on-year decrease of 15.4% [1] - The net profit attributable to shareholders was 3.98 billion yuan, down 20.0% year-on-year [1] - The net profit after deducting non-recurring items was 3.94 billion yuan, a decline of 19.4% year-on-year [1] Coal Production and Sales - The company sold 64.14 million tons of commodity coal in Q1 2025, a slight increase of 0.4% year-on-year [1] - Self-produced commodity coal sales reached 32.68 million tons, up 1.1% year-on-year [1] - The average selling price of coal was 487 yuan/ton, down 17.0% year-on-year, while the average price for self-produced coal was 492 yuan/ton, down 17.7% year-on-year [1][2] Cost and Profitability - The cost of self-produced commodity coal was 270 yuan/ton, a decrease of 7.3% year-on-year [2] - The gross profit per ton of self-produced coal was 222 yuan, down 27.6% year-on-year [2] - Overall coal revenue was 31.25 billion yuan, a decline of 16.6% year-on-year, with operating costs at 23.80 billion yuan, down 13.0% year-on-year [2] Chemical Products Performance - The company sold 355,000 tons of olefins in Q1 2025, a decrease of 4.8% year-on-year, with an average price of 6,876 yuan/ton, up 0.4% year-on-year [2] - Urea sales reached 600,000 tons, an increase of 8.9% year-on-year, with an average price of 1,702 yuan/ton, down 23.9% year-on-year [2] - Methanol sales were 529,000 tons, up 33.6% year-on-year, with an average price of 1,794 yuan/ton, up 7.1% year-on-year, leading to a turnaround in profitability [2] New Capacity and Projects - The company is advancing coal, electricity, and new energy projects, including a stable release of production capacity from the Dahuize coal mine and the upcoming launch of a 400,000-ton/year project [3] - The company is also constructing a 900,000-ton/year polyolefin project and accelerating the development of various renewable energy projects [3] Dividend and Profit Forecast - The company plans to distribute a cash dividend of 0.258 yuan per share for the end of 2024, with a total dividend payout exceeding 30% [3] - Revenue projections for 2025-2027 are 162.1 billion yuan, 156.5 billion yuan, and 156.0 billion yuan, respectively, with a forecasted net profit of 15 billion yuan, 14.7 billion yuan, and 14.6 billion yuan [3]

新产品、新产能、新市场有序拓展，筑牢自身发展基础1）新产品：截至24 年底，公司安全自毁留置 针、双头安全自锁胰岛素笔针头、动物疫苗连续计数注射器、低残留注射器等产品已完成研发并投入生 产；预充式导管冲洗器、营养喂食注射器、精密过滤盒等产品已处于产品试验及生产流程完善阶段。 2）新产能：截至24 年底，公司位于澄鹿路的二期厂房项目已部分完工，海外产能建设正持续推进。 3）新市场：截至24年底，公司多款产品已获得加拿大、沙特等国的产品注册证，新兴市场开拓工作有 序推进。我们看好公司通过新产品、新产能及新市场开发积极收获业绩增量并进一步提升整体抗风险能 力，夯实长期发展基础。 盈利预测与估值 综合考虑公司新产品、新市场开发对于收入增速的拉动及强化产品推广对于销售费用率的影响，我们调 整25-27 年归母净利至0.74/0.83/0.93 亿元（相比25/26 年前值调整-9%/-14%）。公司为注射穿刺器械领 域领军者，产品品类丰富且客户持续拓展，给予公司25 年34x PE （可比公司Wind 一致预期均值 32x），调整目标价至20.59 元（前值18.62 元，对应24 年33x PE）。 公司1Q25 收 ...